Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
40.33
-1.48 (-3.54%)
Nov 17, 2026, 3:04 PM CST
SHE:300049 Revenue
Inner Mongolia Furui Medical Science had revenue of 386.65M CNY in the quarter ending September 30, 2026, a decrease of -0.25%. This brings the company's total for the last twelve months to 1.64B, up 11.26% year-over-year. In the year 2025, Inner Mongolia Furui Medical Science had annual revenue of 1.60B with 18.26% growth. That makes Inner Mongolia Furui Medical Science the 16,015th largest company in the world by revenue and 2,897th in China.
Revenue (ttm)
1.64B
Revenue Growth
+11.26%
P/S Ratio
6.75
Revenue / Employee
1.73M
Employees
946
Market Cap
10.65B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:300049 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | 246.37M | 18.26% |
| Dec 31, 2024 | 1.35B | 195.28M | 16.93% |
| Dec 31, 2023 | 1.15B | 144.97M | 14.37% |
| Jan 1, 2023 | 1.01B | 110.28M | 12.27% |
| Jan 1, 2022 | 898.48M | 90.95M | 11.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.34B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jinyu Bio-technology | 1.60B |
| Nanjing Vazyme Biotech | 1.56B |
| Shanghai Medicilon | 1.54B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| GemPharmatech | 941.80M |